Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

An FDA perspective on preclinical development of cell-based regenerative medicine products

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Characteristics of cell-based regenerative medicine products and preclinical testing programs, based on analysis of 163 IND submissions to the FDA/CBER/OCTGT from 2006 to 2013.

References

  1. United States Code Title 21, Section 312.23(a)(8) http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=312.23.

  2. Bailey, A.M. Sci. Transl. Med. 4, 147fs28 (2012).

    Article  Google Scholar 

  3. Mendicino, M., Bailey, A.M., Wonnacott, K., Puri, R.K. & Bauer, S.R. Cell Stem Cell 14, 141–145 (2014).

    Article  CAS  Google Scholar 

  4. Anatol, R. et al. The regulatory process from concept to market. Principles of Tissue Engineering 1781–1797 (Academic Press, 2013).

  5. Robinson, R., Bailey, A.M. & Ibrahim, S. Sci. Transl. Med. 3, 94ec124 (2011).

    Google Scholar 

Download references

Acknowledgements

We thank C. Gacchina Johnson for her contributions to data analysis of regulatory submissions.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Alexander M Bailey, Michael Mendicino or Patrick Au.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bailey, A., Mendicino, M. & Au, P. An FDA perspective on preclinical development of cell-based regenerative medicine products. Nat Biotechnol 32, 721–723 (2014). https://doi.org/10.1038/nbt.2971

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2971

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research